Which of the following best describes the adverse effects commonly associated with protease inhibitors?

• A. Renal toxicity and hypoglycemia with minimal metabolic effects.
• B. No significant adverse effects; well tolerated in all patients.
• C. Hyperglycemia, dyslipidemia, lipodystrophy, hepatotoxicity, GI upset; drug interactions via CYP450.
• D. Hypertension and thrombocytopenia as the primary effects.

Answer: (C)

Protease inhibitors frequently produce a metabolic and hepatic toxicity pattern along with significant drug interactions. The most common and clinically important effects include hyperglycemia and dyslipidemia, which contribute to a lipodystrophy syndrome characterized by changes in fat distribution; hepatotoxicity with elevated liver enzymes; gastrointestinal upset; and interactions mediated by the cytochrome P450 system, especially when boosted with ritonavir or cobicistat. This combination captures the real-world safety profile of these drugs and explains why this option is the best description of adverse effects. Other statements miss the mark by suggesting minimal adverse effects, or by highlighting hypertension and thrombocytopenia, or by emphasizing renal toxicity and hypoglycemia, which are not the hallmark adverse effects of protease inhibitors.